At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
The purpose of this study is to assess the safety and effectiveness of the drug mosunetuzumab for people with follicular lymphoma who have not yet received treatment. Mosunetuzumab binds to a cancer cell and a T cell (which plays a key role in the immune system) at the same time. Researchers think that mosunetuzumab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Mosunetuzumab is given as a subcutaneous (under the skin) injection.
-
The purpose of this study is to evaluate the safety and effectiveness of cesium-131 (Cs-131) brachytherapy in patients with brain cancer that has come back after prior radiation therapy and who will be having surgery to remove it. Brachytherapy involves the placement of radioactive seeds into the brain during surgery. The seeds remain in place permanently in the area where the tumor was removed and give off cancer-killing radiation temporarily. 
-
Researchers want to find the best dose of BMS-986393 to use with other drugs to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
- A Phase 3 Study Assessing the Addition of Tivozanib to Pembrolizumab Immunotherapy After Surgery for Kidney Cancer
Full Title Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE (A032201) (CIRB)
Purpose
Researchers want to see how well tivozanib plus pembrolizumab works in people with kidney cancer. The people in this study had surgery for renal cell carcinoma and have a high risk of it coming back.
Tivozanib blocks the action of an abnormal protein that tells tumor cells to multiply. This helps stop tumor cell spread. It is taken orally (by mouth).
Pembrolizumab works by helping the immune system attack cancer and inhibiting the growth and spread of tumor cells. It is given intravenously (by vein).
Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone to treat renal cell cancer. If you take part in this study, you will be randomly assigned to get pembrolizumab alone or with tivozanib.
Who Can Join
To join this study, there are a few conditions. You must:
- Have no evidence of cancer after surgery for clear cell renal cell carcinoma. The surgery must have happened at least 4 weeks but no more than 16 weeks before getting the study treatment.
- Have a high risk of kidney cancer coming back.
- Not have had prior anti-cancer medications for kidney cancer.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Darren Feldman’s office at 646-888-4740.
Protocol
25-181Phase
Phase III (phase 3)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06661720ClinicalTrials.gov
-
The standard treatment for poor-risk and intermediate-risk germ cell tumors (GCTs), such as testicular cancer, is chemotherapy with the drugs bleomycin, etoposide, and cisplatin (abbreviated BEP) given every three weeks. In this study, researchers want to see if giving BEP chemotherapy every two weeks is more effective for controlling tumor growth than the standard regimen in patients with metastatic intermediate-risk and poor-risk GCTs.
-
The usual approach to managing HPV-related oropharynx cancer in people whose tumors have a higher risk of coming back after surgery is to use radiation therapy to prevent tumor relapse. However, not all patients have tumors that come back after surgery, and many may not need radiation therapy at all, or only need it later when there are early signs of the cancer coming back.
-
The purpose of this study is to see how well zipalertinib works to treat advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread. The cancer also has a mutation (change) in the EGFR gene. When people have an EGFR mutation, the EGFR protein on their cells can trigger cancer growth.
-
Wilms tumor the most common type of kidney cancer in children. Favorable tissue (histology) Wilms tumors (FHWT) are the most common subtype.
-
Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.
-
In this study, researchers want to see how well a personalized vaccine works for people with pancreatic cancer. The people in this study have pancreatic cancer that can be taken out with surgery. The vaccine is called autogene cevumeran. It is an "mRNA vaccine," made in a way similar to the vaccines used to prevent COVID. It will be given in combination with a drug called atezolizumab and a chemotherapy treatment called mFOLFIRINOX.